We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

By LabMedica International staff writers
Posted on 02 May 2024
Print article
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic imaging such as MRI scans, family medical history, demographic data, and other risk factor evaluations. Often, neurologists only discover that a patient is at risk after they have experienced a stroke or a warning cerebral event. Now, a simple blood test offers the potential for doctors to identify individuals at increased risk for stroke or cognitive decline by measuring levels of a network of inflammatory molecules, which helps calculate a risk score for susceptibility to cerebral small vessel disease.

Researchers at UCLA Health (Los Angeles, CA, USA) have developed a method to measure the concentrations of these inflammatory molecules in individuals who have not yet suffered a cerebrovascular event, thereby providing a quantitative tool to assess the risk for cerebral small vessel disease and potential future strokes. This approach centers around the interleukin-18, or IL-18, network of inflammatory molecules, which includes proteins and signaling molecules that combat various infections. Previous studies have associated certain molecules within the IL-18 network with an increased risk of cerebral small vessel disease and stroke. However, the levels of these molecules can vary in response to various conditions like the flu or autoimmune diseases, rendering them unreliable as sole predictors of stroke risk.

In 2020, this research team discovered that six molecules within the IL-18 network were linked to the presence of vascular brain injuries in MRI scans. Building on these insights, they explored whether the IL-18 network could be used to evaluate a person's likelihood of stroke or cognitive decline. They utilized health data from the long-standing Framingham Heart Study, which has been monitoring the medical histories of residents from Framingham, Massachusetts since its inception in 1948. Blood samples from study participants were analyzed for five of the six molecules identified as part of the IL-18 network.

Using these blood samples and the comprehensive medical histories from the Framingham study, the researchers devised a mathematical model that calculates a risk score based on the concentrations of IL-18 network molecules. Analysis of over 2,200 Framingham participants revealed that individuals with risk scores in the top 25% were 84% more likely to experience a stroke in their lifetime. Moreover, high-risk scores were linked with a 51% increased stroke risk, offering a predictive advantage over traditional risk assessment methods. Further research is necessary to determine whether and how an individual's risk score can be altered or mitigated.

“The same way one uses cholesterol tests to evaluate one’s future risk for heart attack, we don’t have such a thing to estimate future risk for stroke,” said Dr. Jason Hinman of the UCLA who led the study. “I believe we can do that by something as simple as a blood test which in theory can enable broader access to the best level of care and not lock it behind advanced imaging studies and specialist evaluations.”

Related Links:
UCLA Health

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.